After gp350CAR-T cell therapy, 75% of mice controlled or reduced EBV spread and showed lower frequencies of EBER+ B cell malignant lymphoproliferation, lack of tumor development, and reduced inflammation. In summary, CD8+gp350CAR-T cells showed proof-of-concept preclinical efficacy against ...
内容提示: Original ArticleCAR-T Cells Targeting Epstein-Barr Virus gp350Validated in a Humanized Mouse Model ofEBV Infection and Lymphoproliferative DiseaseConstanze Slabik, 1,2,3,14 Maja Kalbarczyk, 1,2,3,14 Simon Danisch, 1,2,3 Reinhard Zeidler, 4,5,6 Frank Klawonn, 7,8Valery Volk, 1...